Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences Trading Down 2.0 %
CALA Stock opened at $3.99 on Tuesday. Calithera Biosciences has a 1 year low of $2.30 and a 1 year high of $49.80. The company has a fifty day simple moving average of $4.20 and a 200 day simple moving average of $6.54. The firm has a market cap of $19.40 million, a PE ratio of -0.14 and a beta of 1.87.
Calithera Biosciences (NASDAQ:CALA - Get Rating) last released its earnings results on Tuesday, May 10th. The biotechnology company reported ($3.60) earnings per share for the quarter, missing analysts' consensus estimates of ($3.40) by ($0.20). During the same period in the previous year, the business earned ($5.60) EPS. As a group, analysts forecast that Calithera Biosciences will post -11.7 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have issued reports on CALA shares. LADENBURG THALM/SH SH decreased their target price on shares of Calithera Biosciences from $60.00 to $30.00 in a research note on Wednesday, May 11th. StockNews.com initiated coverage on shares of Calithera Biosciences in a research note on Tuesday, June 21st. They issued a "hold" rating for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Calithera Biosciences has a consensus rating of "Hold" and a consensus target price of $50.00.